Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017)

PHASE3CompletedINTERVENTIONAL
Enrollment

251

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

October 31, 2015

Study Completion Date

November 30, 2015

Conditions
Relapsing Multiple Sclerosis
Interventions
DRUG

BIIB017

DRUG

naproxen

Trial Locations (38)

11803

Research Site, Plainview

12110

Research Site, Latham

19713

Research Site, Newark

19901

Research Site, Dover

23601

Research Site, Newport News

24018

Research Site, Roanoke

28806

Research Site, Asheville

29607

Research Site, Greenville

30327

Research Site, Atlanta

32209

Research Site, Jacksonville

32901

Research Site, Melbourne

33609

Research Site, Tampa

37064

Research Site, Franklin

37934

Research Site, Knoxville

40207

Research Site, Louisville

40513

Research Site, Lexington

44320

Research Site, Akron

44685

Research Site, Uniontown

45417

Research Site, Dayton

48202

Research Site, Detroit

59405

Research Site, Great Falls

63017

Research Site, Chesterfield

63110

Research Site, St Louis

66160

Research Site, Kansas City

68521

Research Site, Lincoln

73104

Research Site, Oklahoma City

80301

Research Site, Boulder

80528

Research Site, Fort Collins

84103

Research Site, Salt Lake City

85004

Research Site, Phoenix

85018

Research Site, Phoenix

85234

Research Site, Gilbert

85704

Research Site, Tucson

97225

Research Site, Portland

99202

Research Site, Spokane

02135

Research Site, Boston

02421

Research Site, Lexington

01655

Research Site, Worcester

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Biogen

INDUSTRY